Sign In
Buy LGND
$234.40
+1.64 (+0.705%)
At Close: Jun 03, 2026
Ligand to Participate in June Investor Conferences
04:01pm, Wednesday, 27'th May 2026
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c
Saying Goodbye To The XOMA Royalty PFDs
08:00am, Monday, 25'th May 2026
Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or
Ligand Pharmaceuticals Q1 Earnings Call Highlights
04:13pm, Friday, 08'th May 2026
Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from k
Ligand Reports First Quarter 2026 Financial Results
07:00am, Thursday, 07'th May 2026
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
08:01am, Wednesday, 06'th May 2026
NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies
Ligand to Participate in May Investor Conferences
04:01pm, Tuesday, 05'th May 2026
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c
BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook
03:13pm, Wednesday, 29'th Apr 2026
Ligand Pharmaceuticals (NASDAQ: LGND) detailed plans to acquire XOMA Royalty Corporation in an investor call, outlining what executives described as a "highly complementary" transaction intended to ex
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of X
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
03:06pm, Monday, 27'th Apr 2026
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
01:18pm, Monday, 27'th Apr 2026
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Monday said it is expanding its royalty portfolio through the acquisition of XOMA Royalty Corporation (NASDAQ:XOMA).
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
10:01am, Monday, 27'th Apr 2026
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
08:12am, Monday, 27'th Apr 2026
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday.
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
06:00am, Monday, 27'th Apr 2026
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
